These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 26650544)
1. Essential Medicines in a High Income Country: Essential to Whom? Duong M; Moles RJ; Chaar B; Chen TF; PLoS One; 2015; 10(12):e0143654. PubMed ID: 26650544 [TBL] [Abstract][Full Text] [Related]
2. Stakeholder perspectives on the challenges surrounding management and supply of essential medicines. Duong MH; Moles RJ; Chaar B; Chen TF Int J Clin Pharm; 2019 Oct; 41(5):1210-1219. PubMed ID: 31444686 [TBL] [Abstract][Full Text] [Related]
3. Analysis of evidence supporting the Federation of Bosnia and Herzegovina reimbursement medicines lists: role of the WHO Essential Medicines List, Cochrane systematic reviews and technology assessment reports. Mahmić-Kaknjo M; Marušić A Eur J Clin Pharmacol; 2015 Jul; 71(7):825-33. PubMed ID: 25956715 [TBL] [Abstract][Full Text] [Related]
4. Acceptability and feasibility of a national essential medicines list in Canada: a qualitative study of perceptions of decision-makers and policy stakeholders. Jarvis JD; Murphy A; Perel P; Persaud N CMAJ; 2019 Oct; 191(40):E1093-E1099. PubMed ID: 31591095 [TBL] [Abstract][Full Text] [Related]
5. Challenges to pharmaceutical policymaking: lessons from Australia's national medicines policy. Lipworth W; Doran E; Kerridge I; Day R Aust Health Rev; 2014 May; 38(2):160-8. PubMed ID: 24589424 [TBL] [Abstract][Full Text] [Related]
6. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England. Mansfield SJ Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618 [TBL] [Abstract][Full Text] [Related]
7. WHO shapes priorities for medicines? An analysis of the applicants and decision makers within the historical evolution of the WHO Model Lists of Essential Medicines. Jenei K; Glaus CEG; Vokinger KN Lancet; 2024 Oct; 404(10460):1365-1374. PubMed ID: 39368844 [TBL] [Abstract][Full Text] [Related]
9. Access and use of WHO essential medicines in Italy. Petrella A; Fortinguerra F; Cangini A; Pierantozzi A; Trotta F Front Public Health; 2023; 11():1211208. PubMed ID: 37881343 [TBL] [Abstract][Full Text] [Related]
10. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia. Morgan S; McMahon M; Greyson D Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927 [TBL] [Abstract][Full Text] [Related]
11. Estimation of cost-based prices for injectable medicines in the WHO Essential Medicines List. Gotham D; Barber MJ; Hill AM BMJ Open; 2019 Sep; 9(9):e027780. PubMed ID: 31575568 [TBL] [Abstract][Full Text] [Related]
12. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Fundytus A; Sengar M; Lombe D; Hopman W; Jalink M; Gyawali B; Trapani D; Roitberg F; De Vries EGE; Moja L; Ilbawi A; Sullivan R; Booth CM Lancet Oncol; 2021 Oct; 22(10):1367-1377. PubMed ID: 34560006 [TBL] [Abstract][Full Text] [Related]
13. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications. Baxi SM; Beall R; Yang J; Mackey TK Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850 [TBL] [Abstract][Full Text] [Related]
14. Inflated medicine prices in Vietnam: a qualitative study. Nguyen TA; Knight R; Mant A; Razee H; Brooks G; Dang TH; Roughead EE Health Policy Plan; 2017 Jun; 32(5):647-656. PubMed ID: 28453716 [TBL] [Abstract][Full Text] [Related]
15. Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned? Osorio-de-Castro CGS; Azeredo TB; Pepe VLE; Lopes LC; Yamauti S; Godman B; Gustafsson LL Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):402-412. PubMed ID: 29117642 [TBL] [Abstract][Full Text] [Related]
16. Use of evidence and negotiation in the review of national standard treatment guidelines and essential medicines list: experience from Ghana. Koduah A; Asare BA; Gavor E; Gyansa-Lutterodt M; Andrews Annan E; Ofei FW Health Policy Plan; 2019 Nov; 34(Supplement_2):ii104-ii120. PubMed ID: 31723963 [TBL] [Abstract][Full Text] [Related]
17. Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model list of essential medicines. Twagirumukiza M; Annemans L; Kips JG; Bienvenu E; Van Bortel LM Trop Med Int Health; 2010 Mar; 15(3):350-61. PubMed ID: 20070634 [TBL] [Abstract][Full Text] [Related]
18. Stakeholder roles in facilitating access to essential medicines. Duong MH; Moles RJ; Chaar B; Chen TF Res Social Adm Pharm; 2019 Mar; 15(3):260-266. PubMed ID: 29752050 [TBL] [Abstract][Full Text] [Related]
19. Perceptions and utilization of generic medicines in Guatemala: a mixed-methods study with physicians and pharmacy staff. Flood D; Mathieu I; Chary A; García P; Rohloff P BMC Health Serv Res; 2017 Jan; 17(1):27. PubMed ID: 28086866 [TBL] [Abstract][Full Text] [Related]
20. [Mechanism and implication of regulation of the pricing of essential medicines in the private pharmaceutical sector in Mali]. Maïga D; Maïga S; Maïga MD Med Trop (Mars); 2010 Apr; 70(2):184-8. PubMed ID: 20486360 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]